Skip to main content

Table 5 Adjusted ASAS40 response of women versus men after 1 year of treatment with a first TNF inhibitor

From: Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort

Variable A. Response/tolerance analysis B. Completer analysis
OR 95% CI p OR 95% CI p
Female vs. male 0.19 0.05; 0.62 0.009 0.25 0.06; 0.91 0.04
Diagnostic delay 0.97 0.91; 1.03 0.41 0.98 0.90; 1.05 0.66
Modified MASES 0.82 0.61; 1.05 0.14 0.77 0.56; 1.02 0.08
BASDAI 1.24 0.91; 1.75 0.18 1.41 1.00; 2.08 0.06
BMI 0.78 0.64; 0.92 0.008 0.82 0.66; 0.97 0.04
  1. A is the ASAS40 response in patients with available outcome at 1 year, patients having discontinued the first TNFi in the meantime being considered non-responders. B is the ASAS40 response in patients still treated with the first TNF inhibitor at 1 year. Patients with co-morbid fibromyalgia were excluded from both analyses. ASAS40 40% improvement according to the Assessment in SpondyloArthritis International Society criteria, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index; CI confidence interval; MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the plantar fascia in the count, OR odds ratio